In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.
Applegate
Tanya Lynn
TL
Johnson and Johnson Research Pty Ltd, Australian Technology Park, Eveleigh, NSW, Australia. tapplegate@nchecr.unsw.edu.au
Birkett
Donald John
DJ
Mcintyre
Glen John
GJ
Jaramillo
Angel Belisario
AB
Symonds
Geoff
G
Murray
John Michael
JM